Effectiveness of Trauma-Informed Care Programs: A Meta-Analysis.

Trauma Violence AbuseSep 25, 2025 (epub)
Clinical ResearchPsychiatryPediatrics

Shaolingyun Guo, Qiqi Chen, Ko Ling Chan

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis evaluated trauma-informed care (TIC) programs across service systems, including 13 randomized controlled trials published before July 2024. The studies assessed outcomes such as trauma-related knowledge, skills, awareness, and mental health. Random-effects effect sizes were Cohen’s d = 0.72 for programs targeting service providers and d = 1.03 for programs targeting service recipients. Subgroup analyses suggested greater effectiveness in clinical settings, for mental health outcomes, with medical care components, and when programs targeted care or service recipients.

Key findings

  • Across 13 RCTs, the random-effects effect size was Cohen’s d = 0.72 for programs targeting service providers.
  • For programs targeting service recipients, the random-effects effect size was Cohen’s d = 1.03.
  • Subgroup analyses indicated greater effectiveness in clinical settings, for mental health outcomes, with medical care components, and when targeting recipients.

Why it matters

The findings suggest that TIC programs can improve trauma-related knowledge, skills, and awareness, with potential benefits for mental health outcomes across diverse service settings. The stronger reported effect for recipient-targeted programs may help inform program design, while the subgroup results point to clinical settings and medical care components as potentially useful areas for implementation.

What to keep in mind

The meta-analysis included 13 RCTs, and the abstract notes that further research is needed to tailor child-focused interventions for younger populations.

Source

Published in Trauma Violence Abuse. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.